Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sleep trouble linked to heart risk in lung disease patients

NCT ID NCT07464184

Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 60 adults with pulmonary hypertension (high blood pressure in the lungs) for 2 years. Researchers will measure breathing problems during sleep and heart rate changes to see how they relate to the disease. No new treatment is given; participants continue their usual care. The goal is to find better ways to predict and manage health risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 years of age * With precapillary pulmonary hypertension confirmed by pulmonary artery catheterization * With an indication for pulmonary artery vasodilator treatment * Affiliation with a social security system * Women of childbearing age using effective/highly effective contraception (see CTFG) (estrogen-progestogen or intrauterine device or tubal ligation) for 6 months and a negative urine pregnancy test at inclusion, for the duration of the study. * Postmenopausal women: confirmed diagnosis (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit) * Individuals who have read and understood the information letter and signed the consent form Non-Inclusion Criteria: * Treatment with non-invasive ventilation * Eisenmenger syndrome * Systemic scleroderma * Neurodegenerative disease other than isolated peripheral neuropathies. * Untreated and/or uncontrolled cardiac rhythm or conduction disorders, including permanent AF * Untreated coronary artery disease or diagnosis of myocardial infarction within the last six months * Pacemaker wearer * Pregnant or breastfeeding women, or women who are not using reliable contraception * Persons deprived of their liberty by administrative or judicial decision or persons under judicial protection/guardianship or curatorship * History of psychological or sensory illness or abnormality that may prevent the subject from fully understanding the conditions required for participation in the protocol or prevent them from giving their informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic nervous system dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autonomic nervous system disorder heart failure pulmonary arterial hypertension pulmonary hypertension sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autonomic nervous system dysfunction Cardiovascular risk Heart rate variability (HRV) Nocturnal hypoxemia Precapillary pulmonary hypertension Pulmonary arterial hypertension Sleep-disordered breathing

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Rouen

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.